GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (FRA:K3P) » Definitions » Total Equity

Kiadis Pharma NV (FRA:K3P) Total Equity : €-32.92 Mil (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Total Equity?

Kiadis Pharma NV's total equity for the quarter that ended in Dec. 2020 was €-32.92 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Kiadis Pharma NV Total Equity Historical Data

The historical data trend for Kiadis Pharma NV's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Total Equity Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Total Equity
Get a 7-Day Free Trial Premium Member Only 9.44 15.86 44.14 34.26 -32.92

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.14 59.70 34.26 27.59 -32.92

Kiadis Pharma NV Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Kiadis Pharma NV's Total Equity for the fiscal year that ended in Dec. 2020 is calculated as

Total Equity=Total Assets(Q: Dec. 2020 )-Total Liabilities(Q: Dec. 2020 )
=62.762-95.681
=-32.92

Kiadis Pharma NV's Total Equity for the quarter that ended in Dec. 2020 is calculated as

Total Equity=Total Assets(Q: Dec. 2020 )-Total Liabilities(Q: Dec. 2020 )
=62.762-95.681
=-32.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiadis Pharma NV Total Equity Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (FRA:K3P) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (FRA:K3P) » Definitions » Total Equity
Comparable Companies
XAMS:VVY OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY HKSE:02269 OCSE:GMAB HKSE:01177 BMRN SZSE:300122 XBRU:UCB ALNY XAMS:GLPG HKSE:06160
Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Website
https://www.kiadis.com
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (FRA:K3P) Headlines

No Headlines